Combination of in vivo efficacy monitoring with intratumoral biopsy to assess new cancer therapies & decipher their MoA

24 Jan Combination of in vivo efficacy monitoring with intratumoral biopsy to assess new cancer therapies & decipher their MoA

Explicyte is proud to announce the recent development and validation of our new syngeneic subcutaneously-implanted MCA-205 sarcoma tumor mouse model.


Figure 1: Experimental schedule for intratumoral biopsy and efficacy monitoring

Because of its responsiveness to checkpoint blockade and moderate response to chemotherapy (e.g. anti-PD-L1 antibody and doxorubicin, respectively) (Figure 2), the model represents a suitable tool to assess innovative drug candidates for their ability to enhance the anti-tumor response, and characterize their mechanisms of action (MoA) and signaling pathways that contribute to such response.

MCA205 responses

Figure 2: Subcutaneously-implanted MCA-205 sarcoma tumor-bearing mouse model is strongly responsive to PD-L1 blockade and only partially to doxorubicin. Mice were SC inoculated with MCA-205 murine sarcoma cells and exposed to anti-PD-L1 antibody or doxorubicin. Tumor growth was monitored overtime. Tumor volume (A) and survival (B) were then determined.

Indeed in a very interesting way, we characterized the immunomodulation mechanisms underlying the pharmacological response to anti-PD-L1 antibody, by gene expression analysis* on intratumoral biopsies collected from the same mice monitored for efficacy (fig. 1). This methodology and data analysis allowed to highlight a correlation between key gene expression modifications (e.g. Ifng) and survival effects triggered by the treatment (Figure 3). Altogether, these results show that performing intratumoral biopsy on our preclinical models (simultaneously with efficacy monitoring), is a well-suited approach to delineate MoA of candidate compounds, or identify a biomarker predictive for the pharmacological in vivo response.

Correlation Survival vs Gene expression - Tumor biopsy

Figure 3: Analysis of the correlation between key immune marker encoding genes and survival.  Changes in the intratumoral expression of selected immune marker encoding genes are correlated with survival of MCA-205 tumor-bearing mice treated with anti-PD-L1 antibody (A). An example of a significant correlation is illustrated in (B) for Ifng gene expression. Mice showing high intratumoral Ifng gene expression (IfngHigh) display the longest survival, compared to those with a lower Ifng gene expression (IfngLow).

* Other methodologies and platforms e.g. FACS immunophenotyping… are available

Contact us to assess your candidate drug(s)!

contact us

 I agree with the use of my personal data for further communications according to explicyte privacy policy

Combination of intratumoral biopsy with in vivo efficacy monitoring to assess new cancer therapies & decipher their MoA